{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:48:59Z","timestamp":1791776939144,"version":"4.3.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Allergen immunotherapy (AIT) and venom immunotherapy (VIT) are meant to work on the causes of allergies, respectively, to respiratory allergens and Hymenoptera venom, inducing tolerance to the allergens and modifying the natural history of allergy. Both types of immunotherapies have evidence of efficacy, but actually they present wide differences in both effectiveness and safety. Indeed, as far as the effectiveness of VIT is concerned, if the protection against fatal reactions to stings is considered as the primary objective, more than 40 years of clinical practice demonstrate complete success. The clinical success of AIT is measurable on the basis of reduction or disappearance of allergic symptoms. The difference between the two treatments is even higher as regards safety: AIT has been concerned in the past by a series of fatal reactions caused, which underwent a progressive decrease when it was understood that they were related to the presence of uncontrolled asthma. However, fatal reactions related to failure to recognize the presence of risk factors or administration errors are still reported. Similarly to what has been observed for efficacy, VIT has never been affected by fatal reactions to the administration of venom, and the most important risk of anaphylaxis, which is the concomitance of mastocytosis, is now identified by measuring its marker serum tryptase. To date, mechanisms of hypersensitivity reactions that differentiate respiratory allergy from Hymenoptera venom allergy have not been successfully demonstrated. We have examined the past and present literature in order to propose reasonable hypotheses about the mechanisms actually involved.<\/jats:p>","DOI":"10.3389\/falgy.2022.854080","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T02:01:01Z","timestamp":1644976861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?"],"prefix":"10.3389","volume":"3","author":[{"given":"Cristoforo","family":"Incorvaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Ridolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pucciarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11882-020-00908-6","article-title":"Peanut oral immunotherapy: a current perspective","volume":"20","author":"Patrawala","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0091-6749(97)70270-7","article-title":"Natural history of Hymenoptera venom sensitivity in adults","volume":"100","author":"Golden","year":"1997","journal-title":"J Allergy Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0095-4543(21)00816-2","article-title":"Stinging insect allergy","volume":"6","author":"Pence","year":"1979","journal-title":"Prim Care."},{"key":"B4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJM197807272990401","article-title":"A controlled trial of immunotherapy in insect hypersensitivity","volume":"299","author":"Hunt","year":"1978","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/0091-6749(92)90073-B","article-title":"Imported fire ant immunotherapy: effectiveness of whole body extracts","volume":"90","author":"Freeman","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1111\/all.13851","article-title":"Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care","volume":"74","author":"Breiteneder","year":"2019","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaci.2015.04.047","article-title":"International consensus on allergy immunotherapy","volume":"136","author":"Jutel","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/ACI.0000000000000570","article-title":"Insect sting allergy: new guidelines from the European and USA consensus groups: algorithms and recommendations","volume":"19","author":"Golden","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1067\/mai.2001.119154","article-title":"Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses","volume":"108","author":"Ru\u00ebff","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0091-6749(97)70314-2","article-title":"Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis","volume":"99","author":"Oude Elberink","year":"1997","journal-title":"J Allergy Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/all.13945","article-title":"Risk factors and indicators of severe systemic insect sting reactions","volume":"75","author":"Stoevesandt","year":"2020","journal-title":"Allergy."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1080\/21645515.2019.1614397","article-title":"Responders and nonresponders to pharmacotherapy and allergen immunotherapy","volume":"15","author":"Jakalski","year":"2019","journal-title":"Hum Vaccines Immunother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/alr.22508","article-title":"Predictive methods for efficacy of house dust mite subcutaneous immunotherapy in allergic rhinitis patients","volume":"10","author":"Liu","year":"2020","journal-title":"Forum Allergy Rinol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000505746","article-title":"Enhanced efficacy of dust mite sublingual immunotherapy in low-response allergic rhinitis patients after dose increment at 6 months: a prospective study","volume":"181","author":"Gao","year":"2020","journal-title":"Int Arch Allergy Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11882-021-01008-9","article-title":"Regulatory requirements for the quality of allergen products for allergen immunotherapy of food allergy","volume":"21","author":"Englert","year":"2021","journal-title":"Curr Allergy Asthma Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaip.2019.11.027","article-title":"Global trends in anaphylaxis epidemiology and clinical implications","volume":"8","author":"Turner","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0091-6749(97)70135-0","article-title":"Effficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial","volume":"100","author":"Brockow","year":"1997","journal-title":"J Allergy Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/cea.12997","article-title":"Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose","volume":"47","author":"Stretz","year":"2017","journal-title":"Clin Exp Allergy."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/0091-6749(93)90030-J","article-title":"Survey of fatalities from skin testing and immunotherapy 1985-1989","volume":"92","author":"Reid","year":"1993","journal-title":"J Allergy Clin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/bmj.307.6909.919","article-title":"Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party","volume":"307","author":"Frew","year":"1993","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.anai.2021.03.011","article-title":"Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma","volume":"127","author":"Epstein","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaci.2013.12.1088","article-title":"Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens","volume":"133","author":"Akdis","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1365-2222.2006.02487.x","article-title":"A Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy","volume":"36","author":"Mamessier","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1398-9995.1994.tb00796.x","article-title":"Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy","volume":"49","author":"Pucci","year":"1994","journal-title":"Allergy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1517\/14656566.2011.616494","article-title":"Safety of hymenoptera venom immunotherapy: a systematic review","volume":"12","author":"Incorvaia","year":"2011","journal-title":"Expert Opin Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.3390\/ijerph18084011","article-title":"New biomarkers of Hymenoptera venom allergy in a group of inflammation factors","volume":"18","author":"Pack","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jaip.2020.12.036","article-title":"Biologic therapy in allergy practice: a new era in treatment has begun","volume":"9","author":"Wu","year":"2021","journal-title":"J Allergy Clin Immunol Pract."}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.854080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T02:01:03Z","timestamp":1644976863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.854080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":27,"alternative-id":["10.3389\/falgy.2022.854080"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2022.854080","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/WJ5N3V","asserted-by":"object"}]},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"article-number":"854080"}}